BC Innovations | Apr 1, 2019
Emerging Company Profile

Arixa: Breaking resistance with oral beta lactamase inhibitors

Arixa has made an IV antibiotic oral with prodrug chemistry. Arixa Pharmaceuticals Inc. is modifying diazabicyclooctanes, a class of β-lactamase inhibitors that suffer from poor absorption across the GI tract, for use in combination with...
BC Innovations | Jun 9, 2016
Distillery Therapeutics

Therapeutics: Nuclear factor (erythroid-derived 2)-like 2 (NFE2L2; NRF2)

Other INDICATION: Progeria Patient sample, cell culture and mouse studies suggest promoting NFE2L2 activity could help treat Hutchinson-Gilford progeria syndrome (HGPS). In patient fibroblasts, NFE2L2 activity was lower than in fibroblasts from healthy volunteers. Also...
BC Week In Review | May 30, 2016
Company News

XenoPort, Arbor Pharmaceuticals deal

Specialty pharma Arbor will acquire XenoPort for $7.03 per share in a cash deal the companies say values XenoPort at $467 million. The price is a 60% premium to XenoPort’s close of $4.40 on May...
BC Extra | May 24, 2016
Company News

Arbor acquiring XenoPort

Specialty pharma Arbor Pharmaceuticals Inc. (Atlanta, Ga.) is acquiring XenoPort Inc. (NASDAQ:XNPT) for $7.03 per share, or about $467 million. The deal will give Arbor rights to Horizant gabapentin enacarbil , which is approved in the...
BC Week In Review | Apr 4, 2016
Company News

XenoPort, Dr. Reddy’s Laboratories Ltd. deal

XenoPort granted Dr. Reddy’s exclusive, U.S. rights to develop and commercialize XP23829 . XenoPort will receive $47.5 million up front and is eligible for up to $190 million in regulatory milestones and $250 million in commercial...
BC Extra | Mar 29, 2016
Company News

Dr. Reddy's, XenoPort strike deal for psoriasis therapy

XenoPort Inc. (NASDAQ:XNPT) granted Dr. Reddy%27s Laboratories Ltd. (NYSE:RDY) exclusive, U.S. rights to develop and commercialize XP23829 , which has completed a Phase II trial to treat moderate to severe chronic plaque-type psoriasis. The compound is...
BioCentury | Jan 4, 2016
Finance

Big band swing

Many investors treated biotech's dismal 3Q15 as a buying opportunity, and the effects were apparent in 4Q15. All of the market cap bands showed positive gains save for the microcaps. Big biotechs led the charge...
BC Week In Review | Oct 12, 2015
Clinical News

XP23829: Development discontinued

XenoPort discontinued development of XP23829 and plans to partner the compound and other pipeline candidates to focus on commercializing Horizant gabapentin enacarbil. In September, XenoPort reported data from a Phase II trial of XP23829 to...
BC Week In Review | Oct 12, 2015
Company News

XenoPort neurology, autoimmune news

XenoPort will reduce headcount by 25 (14%) to about 155 and plans to partner XP23829 and other pipeline candidates to focus on commercializing Horizant gabapentin enacarbil. Cuts include positions related to the XP23829 program. Additionally,...
BC Innovations | Oct 8, 2015
Distillery Therapeutics

Therapeutics: Kelch-like ECH-associated protein 1 (KEAP1); nuclear factor (erythroid-derived 2)-like 2 (NFE2L2; NRF2)

Hematology INDICATION: Sickle cell disease Mouse studies suggest inhibiting KEAP1 or activating NFE2L2 could help treat sickle cell disease. In a mouse model of sickle cell disease, KEAP1 knockdown increased NFE2L2 levels in the liver...
Items per page:
1 - 10 of 388
BC Innovations | Apr 1, 2019
Emerging Company Profile

Arixa: Breaking resistance with oral beta lactamase inhibitors

Arixa has made an IV antibiotic oral with prodrug chemistry. Arixa Pharmaceuticals Inc. is modifying diazabicyclooctanes, a class of β-lactamase inhibitors that suffer from poor absorption across the GI tract, for use in combination with...
BC Innovations | Jun 9, 2016
Distillery Therapeutics

Therapeutics: Nuclear factor (erythroid-derived 2)-like 2 (NFE2L2; NRF2)

Other INDICATION: Progeria Patient sample, cell culture and mouse studies suggest promoting NFE2L2 activity could help treat Hutchinson-Gilford progeria syndrome (HGPS). In patient fibroblasts, NFE2L2 activity was lower than in fibroblasts from healthy volunteers. Also...
BC Week In Review | May 30, 2016
Company News

XenoPort, Arbor Pharmaceuticals deal

Specialty pharma Arbor will acquire XenoPort for $7.03 per share in a cash deal the companies say values XenoPort at $467 million. The price is a 60% premium to XenoPort’s close of $4.40 on May...
BC Extra | May 24, 2016
Company News

Arbor acquiring XenoPort

Specialty pharma Arbor Pharmaceuticals Inc. (Atlanta, Ga.) is acquiring XenoPort Inc. (NASDAQ:XNPT) for $7.03 per share, or about $467 million. The deal will give Arbor rights to Horizant gabapentin enacarbil , which is approved in the...
BC Week In Review | Apr 4, 2016
Company News

XenoPort, Dr. Reddy’s Laboratories Ltd. deal

XenoPort granted Dr. Reddy’s exclusive, U.S. rights to develop and commercialize XP23829 . XenoPort will receive $47.5 million up front and is eligible for up to $190 million in regulatory milestones and $250 million in commercial...
BC Extra | Mar 29, 2016
Company News

Dr. Reddy's, XenoPort strike deal for psoriasis therapy

XenoPort Inc. (NASDAQ:XNPT) granted Dr. Reddy%27s Laboratories Ltd. (NYSE:RDY) exclusive, U.S. rights to develop and commercialize XP23829 , which has completed a Phase II trial to treat moderate to severe chronic plaque-type psoriasis. The compound is...
BioCentury | Jan 4, 2016
Finance

Big band swing

Many investors treated biotech's dismal 3Q15 as a buying opportunity, and the effects were apparent in 4Q15. All of the market cap bands showed positive gains save for the microcaps. Big biotechs led the charge...
BC Week In Review | Oct 12, 2015
Clinical News

XP23829: Development discontinued

XenoPort discontinued development of XP23829 and plans to partner the compound and other pipeline candidates to focus on commercializing Horizant gabapentin enacarbil. In September, XenoPort reported data from a Phase II trial of XP23829 to...
BC Week In Review | Oct 12, 2015
Company News

XenoPort neurology, autoimmune news

XenoPort will reduce headcount by 25 (14%) to about 155 and plans to partner XP23829 and other pipeline candidates to focus on commercializing Horizant gabapentin enacarbil. Cuts include positions related to the XP23829 program. Additionally,...
BC Innovations | Oct 8, 2015
Distillery Therapeutics

Therapeutics: Kelch-like ECH-associated protein 1 (KEAP1); nuclear factor (erythroid-derived 2)-like 2 (NFE2L2; NRF2)

Hematology INDICATION: Sickle cell disease Mouse studies suggest inhibiting KEAP1 or activating NFE2L2 could help treat sickle cell disease. In a mouse model of sickle cell disease, KEAP1 knockdown increased NFE2L2 levels in the liver...
Items per page:
1 - 10 of 388